 |
RBC Capital Markets®
|
Filed Pursuant to Rule 433
Registration Statement No. 333-227001
|
|
|
The information in this preliminary terms supplement is not complete and may be changed.
|
|||
|
Preliminary Terms Supplement
Subject to Completion:
Dated February 12, 2019
Pricing Supplement dated February __ 2019 to the Product Prospectus Supplement Dated September 10, 2018, the Prospectus Supplement Dated
September 7, 2018 and the Prospectus Dated September 7, 2018
|
$
Issuer Callable Fixed Coupon Notes due
February 19, 2021
Linked to the Lesser Performing of Three
Equity Securities
Royal Bank of Canada
|
||
|
|
|
||
Royal Bank of Canada is offering Issuer Callable Fixed Coupon Notes (the “Notes”) linked to the lesser performing of the three equity
securities set forth below. The Notes are senior unsecured obligations of Royal Bank of Canada,
will pay a monthly coupon at the interest rate specified below, and will have the terms described in the documents described above, as supplemented or modified by this
terms supplement, as set forth below.
The Notes do not guarantee any return of principal at maturity. Any
payments on the Notes are subject to our credit risk.
Investing in the Notes involves a number of risks. See “Risk Factors”
beginning on page S-1 of the prospectus supplement dated September 7, 2018, “Additional Risk Factors Specific to Your Notes” beginning on page PS-3 of the product prospectus supplement dated September 10, 2018 and “Selected Risk Considerations”
beginning on page P-6 of this terms supplement.
The Notes will not constitute deposits insured by the
Canada Deposit Insurance Corporation, the U.S. Federal Deposit Insurance Corporation or any other Canadian or U.S. government agency or instrumentality. The Notes are not subject to conversion into our common shares under subsection 39.2(2.3) of
the Canada Deposit Insurance Corporation Act.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the Notes or determined that this
terms supplement is truthful or complete. Any representation to the contrary is a criminal offense.
|
Issuer:
|
Royal Bank of Canada
|
Stock Exchange Listing:
|
None
|
|
Trade Date:
|
February 13, 2019
|
Principal Amount:
|
$1,000 per Note
|
|
Issue Date:
|
February 19, 2019
|
Coupon Payments:
|
Each coupon will be paid in equal monthly payments, unless the Notes are previously called
|
|
Reference Stocks and Reference Stock Issuers
|
Initial Stock Prices*
|
Barrier Prices
|
||
|
Allergan PLC (“AGN”)
|
50.00% of its Initial Stock Price
|
|||
|
Bristol-Myers Squibb Company (“BMY”)
|
50.00% of its Initial Stock Price
|
|||
|
Gilead Sciences, Inc. (“GILD”)
|
50.00% of its Initial Stock Price
|
* For each Reference Stock, its closing price on the Trade Date.
|
Final Stock Price:
|
The closing price of each Reference Stock on the Valuation Date.
|
|
Call Feature:
|
The Notes may be called at our discretion on any Coupon Payment Date, beginning six months after issuance, if we send prior written notice, as
described below.
|
|
Payment at Maturity (if held to
maturity):
|
For each $1,000 in principal amount of the Notes, the investor will receive $1,000 plus any accrued and unpaid interest at maturity, unless:
(i) the Final Stock Price of the Lesser Performing Reference Stock is less than its Initial Stock Price; and (ii) on any day during the Monitoring Period, the
closing price of any Reference Stock is less than its Barrier Price. If the conditions described in (i) and (ii) are both satisfied, then the investor will receive at maturity, in addition to accrued and unpaid interest, for each $1,000 in
principal amount, the number of shares of the Lesser Performing Reference Stock equal to the Physical Delivery Amount, or at our election, the cash value of those shares.
Investors in the Notes could lose some or all of their initial investment if there has been a decline in
the trading price of the Lesser Performing Reference Stock.
|
|
Physical Delivery Amount:
|
For each $1,000 in principal amount, a number of shares of the Lesser Performing Reference Stock equal to the principal amount
divided by the Initial Stock Price, subject to adjustment as described in the product prospectus supplement.
|
|
Monitoring Period:
|
From and excluding the Trade Date to and including the Valuation Date
|
|
Term of Notes
|
CUSIP
|
Coupon Rate
|
Price to Public(1)
|
Agent’s Commission(1)
|
Proceeds to Royal Bank of Canada
|
||||||
|
Two (2) years
|
78013GHP3
|
11% per annum
|
100%
|
1.85%
|
98.15%
|
(1) Certain dealers who purchase the Notes for sale to certain fee-based advisory accounts may forego some or all of their underwriting
discount or selling concessions. The public offering price for investors purchasing the Notes in these accounts may be between $981.50 and $1,000 per $1,000 in principal amount.
The initial estimated value of the Notes as of the date of this terms supplement is $965.08 per $1,000 in principal amount, which is
less than the price to public. The final pricing supplement relating to the Notes will set forth our estimate of the initial value of the Notes as of the Trade Date, which will not be less than $945.08 per $1,000 in principal amount. The actual
value of the Notes at any time will reflect many factors, cannot be predicted with accuracy, and may be less than this amount. We describe our determination of the initial estimated value in more detail below.
If the Notes priced on the date of this terms supplement, RBC Capital Markets, LLC, which we refer to as RBCCM, acting as agent for
Royal Bank of Canada, would receive a commission of approximately $18.50 per $1,000 in principal amount of the Notes and would use a portion of that commission to allow selling concessions to other dealers of up to approximately $18.50 per $1,000
in principal amount of the Notes. The other dealers may forgo, in their sole discretion, some or all of their selling concessions. See “Supplemental Plan of Distribution (Conflicts of Interest)” below.
RBC Capital Markets, LLC
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
SUMMARY
The information in this “Summary” section is qualified by the more detailed information set forth in this terms supplement, the product prospectus
supplement, the prospectus supplement, and the prospectus.
|
General:
|
This terms supplement relates to an offering of Issuer Callable Fixed Coupon Notes (the “Notes”) linked to the lesser performing of three
equity securities (each a “Reference Stock,” and collectively, the “Reference Stocks”).
|
|
Issuer:
|
Royal Bank of Canada (“Royal Bank”)
|
|
Trade Date (Pricing
Date):
|
February 13, 2019
|
|
Issue Date:
|
February 19, 2019
|
|
Denominations:
|
Minimum denomination of $1,000, and integral multiples of $1,000 thereafter.
|
|
Designated Currency:
|
U.S. Dollars
|
|
Coupon Rate:
|
11% per annum (approximately 0.9167% per month).
|
|
Coupon Payment:
|
Each coupon will be paid in equal monthly payments, unless the Notes are previously called.
|
|
Coupon Payment
Dates:
|
March 18, 2019, April 18, 2019, May 16, 2019, June 18, 2019, July 18, 2019, August 16, 2019, September 18, 2019, October 17,
2019, November 18, 2019, December 18, 2019, January 16, 2020, February 19, 2020, March18, 2020, April 16, 2020, May 18, 2020, June 18, 2020, July 16, 2020, August 18, 2020, September 17, 2020, October 16, 2020, November 18, 2020, December
17, 2020, January 19, 2021 and the Maturity Date.
|
|
Call Feature:
|
The Notes may be called at our discretion on any Coupon Payment Date beginning in August 2019, if we send prior written notice to the
trustee at least three business days prior to that Coupon Payment Date.
|
|
Payment if Called:
|
If the Notes are called, then, on the applicable Coupon Payment Date, beginning August 2019, for each $1,000 principal amount, you will
receive $1,000 plus any accrued and unpaid interest to but excluding the applicable Coupon Payment Date.
|
|
Valuation Date:
|
February 16, 2021
|
|
Maturity Date:
|
February 19, 2021, unless we call the Notes.
|
|
Reference Stocks:
|
Allergan PLC (“AGN”), Bristol-Myers Squibb Company (“BMY”) and Gilead Sciences, Inc. (“GILD”).
|
|
Lesser Performing
Reference Stock:
|
The Reference Stock with the lowest Reference Stock Return.
|
|
Reference Stock
Return:
|
With respect to each Reference Stock:
Final Stock Price – Initial Stock Price
Initial Stock Price
|
|
Initial Stock Prices:
|
For each Reference Stock, its closing price on the Trade Date.
|
|
Barrier Prices:
|
For each Reference Stock, 50.00% of its Initial Stock Price.
|
|
Final Stock Prices:
|
For each Reference Stock, its closing price on the Valuation Date.
|
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
|
Payment at Maturity (if
held to maturity):
|
For each $1,000 in principal amount of the Notes, the investor will receive $1,000 plus any accrued and unpaid interest at maturity,
unless: (i) the Final Stock Price of the Lesser Performing Reference Stock is less than its Initial Stock Price; and (ii) on any day during the Monitoring Period, the closing price of the Reference Stock is less than its Barrier Price (a
“Barrier Event”).
If the conditions described in (i) and (ii) are both satisfied, then the investor will receive at maturity, in addition to accrued and unpaid
interest, for each $1,000 in principal amount in the Notes, the number of shares of the Lesser Performing Reference Stock equal to the Physical Delivery Amount, or at our election, the Cash Delivery Amount. If we elect to deliver shares of
the Lesser Performing Reference Stock, fractional shares will be paid in cash.
The value of the cash or shares that you receive will be less than your principal amount, if anything, resulting in a loss that is
proportionate to the decline of the Lesser Performing Reference Stock from the Trade Date to the Valuation Date. Investors in the Notes could lose
some or all of their initial investment if there has been a decline in the trading price of the Lesser Performing Reference Stock.
|
|
Physical Delivery
Amount:
|
For each $1,000 in principal amount, a number of shares of the Lesser Performing Reference Stock equal to the principal
amount divided by its Initial Stock Price, subject to adjustment as described in the product prospectus supplement. If this number is not a round number, then the number of shares of the Lesser Performing Reference Stock to be delivered
will be rounded down and the fractional part shall be paid in cash.
|
|
Cash Delivery Amount:
|
The product of the Physical Delivery Amount multiplied by the Final Stock Price of the Lesser Performing Reference Stock.
|
|
Monitoring Period:
|
From and excluding the Trade Date to and including the Valuation Date.
|
|
Monitoring Method:
|
Close of Trading Day.
|
|
Physical Delivery:
|
Not applicable. The payments on the Notes will be made solely in cash.
|
|
Calculation Agent:
|
RBC Capital Markets, LLC (“RBCCM”)
|
|
Secondary Market:
|
RBCCM (or one of its affiliates), though not obligated to do so, may maintain a secondary market in the Notes after the Issue Date. The
amount that you may receive upon sale of your Notes prior to maturity may be less than the principal amount of your Notes.
|
|
Listing:
|
None
|
|
Settlement:
|
DTC global (including through its indirect participants Euroclear and Clearstream, Luxembourg as described under “Description of Debt
Securities—Ownership and Book-Entry Issuance” in the prospectus dated September 7, 2018).
|
|
Terms Incorporated in
the Master Note:
|
All of the terms appearing above the item captioned “Secondary Market” on the cover page and pages P-2 and P-3 of this terms
supplement and the terms appearing under the caption “General Terms of the Notes” in the product prospectus supplement, as modified by this terms supplement.
|
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
ADDITIONAL TERMS OF YOUR NOTES
You should read this terms supplement together with the prospectus dated September 7, 2018, as supplemented by the prospectus supplement dated
September 7, 2018 and the product prospectus supplement dated September 10, 2018, relating to our Senior Global Medium-Term Notes, Series H, of which these Notes are a part. Capitalized terms used but not defined in this terms supplement will have
the meanings given to them in the product prospectus supplement. In the event of any conflict, this terms supplement will control. The Notes vary from the
terms described in the product prospectus supplement in several important ways. You should read this terms supplement carefully.
This terms supplement, together with the documents listed below, contains the terms of the Notes and supersedes all prior or contemporaneous oral
statements as well as any other written materials including preliminary or indicative pricing terms, correspondence, trade ideas, structures for implementation, sample structures, brochures or other educational materials of ours. You should
carefully consider, among other things, the matters set forth in “Risk Factors” in the prospectus supplement dated September 7, 2018 and “Additional Risk Factors Specific to Your Notes” in the product prospectus supplement dated September 10, 2018,
as the Notes involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisors before you invest in the Notes. You may access these documents on the Securities and
Exchange Commission (the “SEC”) website at www.sec.gov as follows (or if that address has changed, by reviewing our filings for the relevant date on the SEC website):
Prospectus dated September 7, 2018:
Prospectus Supplement dated September 7, 2018:
Product Prospectus Supplement dated September 10, 2018:
Our Central Index Key, or CIK, on the SEC website is 1000275. As used in this terms supplement, “we,” “us,” or “our” refers to Royal
Bank of Canada.
Royal Bank of Canada has filed a registration statement (including a product prospectus supplement, a prospectus supplement, and a prospectus) with the SEC for the
offering to which this terms supplement relates. Before you invest, you should read those documents and the other documents relating to this offering that we have filed with the SEC for more complete information about us and this offering. You
may obtain these documents without cost by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Royal Bank of Canada, any agent or any dealer participating in this offering will arrange to send you the product prospectus supplement,
the prospectus supplement and the prospectus if you so request by calling toll-free at 1-877-688-2301.
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
HYPOTHETICAL EXAMPLES OF AMOUNTS PAYABLE AT MATURITY
The examples set forth below are provided for illustration
purposes only. The assumptions in each of the examples are purely hypothetical and do not relate to the actual performance of any Reference Stock. The hypothetical terms do not purport to be representative of every possible scenario concerning
increases or decreases in the price of each Reference Stock on the Valuation Date relative to its price on the Trade Date. We cannot predict the actual performance of
each Reference Stock.
The table below illustrates the Payment at Maturity of the Notes (excluding the final Coupon), assuming an Initial Stock Price of
$100, a Barrier Price of 50% and an initial investment of $1,000. Hypothetical Final Stock Prices of the Lesser Performing Reference Stock are shown in the first column on the left. For this purpose, we have assumed that there will be no
anti-dilution adjustments to the Final Stock Price and no market disruption events. The second column shows the Payment at Maturity (as a percentage of the principal amount) in a case where the closing price of none of the Reference Stocks falls
below its Barrier Price at any time during the Monitoring Period. The third column shows the Payment at Maturity (as a percentage of the principal amount) in a case where the closing price of at least one Reference Stock falls below its Barrier
Price during the Monitoring Period. The fourth column shows the Physical Delivery Amount as a number of shares of the Lesser Performing Reference Stock. The fifth column shows the Cash Delivery Amount, should we elect to deliver the Cash Delivery
Amount instead of the Physical Delivery Amount.
|
Hypothetical
Final Stock
Price
|
If the closing market price of none of
the Reference Stocks falls below the
Barrier Price on any day during the
Monitoring Period:
Payment at Maturity as Percentage of
Principal Amount
|
If the closing market price of at least
one Reference Stock falls below its
Barrier Price on any day during the Monitoring Period:
Payment at Maturity as Percentage
of Principal Amount
|
Physical Delivery
Amount as
Number of Shares
of the Least
Performing
Reference Stock
|
Cash
Delivery
Amount
|
|
$200.00
|
100.00%
|
100.00%
|
n/a
|
n/a
|
|
$175.00
|
100.00%
|
100.00%
|
n/a
|
n/a
|
|
$150.00
|
100.00%
|
100.00%
|
n/a
|
n/a
|
|
$125.00
|
100.00%
|
100.00%
|
n/a
|
n/a
|
|
$100.00
|
100.00%
|
100.00%
|
n/a
|
n/a
|
|
$90.00
|
100.00%
|
90.00%
|
10
|
$900
|
|
$80.00
|
100.00%
|
80.00%
|
10
|
$800
|
|
$75.00
|
100.00%
|
75.00%
|
10
|
$750
|
|
$50.00
|
100.00%
|
50.00%
|
10
|
$500
|
|
$40.00
|
n/a
|
Physical Delivery Amount or Cash Settlement Amount
|
10
|
$400
|
|
$30.00
|
n/a
|
Physical Delivery Amount or Cash Settlement Amount
|
10
|
$300
|
|
$25.00
|
n/a
|
Physical Delivery Amount or Cash Settlement Amount
|
10
|
$250
|
|
$0.00
|
n/a
|
Physical Delivery Amount or Cash Settlement Amount
|
10
|
$0.00
|
The Payments at Maturity shown above are entirely hypothetical; they are based on market prices for the Reference Stocks that may not be achieved on
the Valuation Date and on assumptions that may prove to be erroneous. The actual market value of your Notes on the Maturity Date or at any other time, including any time you may wish to sell your Notes, may bear little relation to the hypothetical
Payments at Maturity shown above, and those amounts should not be viewed as an indication of the financial return on an investment in the Notes or on an investment in any Reference Stock. Please read “Additional Risk Factors Specific to Your
Notes” and “Hypothetical Returns on Your Notes” in the accompanying product prospectus supplement.
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
SELECTED RISK CONSIDERATIONS
An investment in the Notes involves significant risks. Investing in the Notes is not equivalent to investing directly in the Reference Stocks. These
risks are explained in more detail in the section “Additional Risk Factors Specific to Your Notes” in the product prospectus supplement. In addition to the risks described in the prospectus supplement and the product prospectus supplement, you
should consider the following:
| · |
Principal at Risk — Investors in the Notes could lose all or a substantial portion of their principal
amount if there is a decline in the closing price of the Lesser Performing Reference Stock between the Trade Date and the Valuation Date. If the Notes are not called, a Barrier Event has occurred, and the Final Stock Price of the Lesser
Performing Reference Stock on the Valuation Date is less than its Initial Stock Price, the value of the cash or shares that you receive at maturity will represent a loss of your principal that is proportionate to the decline in the
closing price of the Lesser Performing Reference Stock from the Trade Date to the Valuation Date. If you receive shares of the Lesser Performing Reference Stock, their value could decrease further between the Valuation Date and the
Maturity Date. The rate of interest payable on the Notes may not be sufficient to compensate for any such loss.
|
| · |
The Notes Are Subject to an Issuer Call — We may call the Notes at our discretion on any Coupon Payment
Date beginning in August 2019. If the Notes are called, then, for each $1,000 in principal amount, you will receive $1,000 plus any accrued and unpaid interest to but excluding the applicable Coupon Payment Date. You will not receive
any coupon payments after the Notes are called. You may be unable to reinvest your proceeds from the call in an investment with a return that is as high as the return on the Notes would have been if they had not been called.
|
| · |
The Notes Are Linked to the Lesser Performing Reference Stock, Even if the Other Reference Stocks Perform Better
— If a Barrier Event occurs, and if any of the Reference Stocks has a Final Stock Price that is less than its Initial Stock Price, your return will be linked to the lesser performing of the Reference Stocks. Even if the Final Stock
Prices of the other Reference Stocks have increased compared to their Initial Stock Prices, or have experienced a decrease that is less than that of the Lesser Performing Reference Stock, your return will only be determined by reference
to the performance of the Lesser Performing Reference Stock, regardless of the performance of the other Reference Stocks.
|
| · |
Your Payment on the Notes Will Be Determined by Reference to Each Reference Stock Individually, Not to a Basket,
and the Payment at Maturity Will Be Based on the Performance of the Lesser Performing Reference Stock — The Payment at Maturity will be determined only by reference to the performance of the Lesser Performing Reference Stock,
regardless of the performance of the other Reference Stocks. The Notes are not linked to a weighted basket, in which the risk may be mitigated and diversified among each of the basket components. For example, in the case of notes linked
to a weighted basket, the return would depend on the weighted aggregate performance of the basket components reflected as the basket return. As a result, the depreciation of one basket component could be mitigated by the appreciation of
the other basket components, as scaled by the weighting of that basket component. However, in the case of the Notes, the individual performance of each Reference Stock would not be combined, and the depreciation of one Reference Stock
would not be mitigated by any appreciation of the other Reference Stocks. Instead, if a Barrier Event has occurred, your return will depend solely on the Final Stock Price of the Lesser Performing Reference Stock.
|
| · |
The Call Feature Limits Your Potential Return — The return potential of the Notes is limited to the
pre-specified Coupon Rate, regardless of the appreciation of the Reference Stocks. If the Notes are called due to the call, you will not receive any Coupon Payments after the applicable Coupon Payment Date. Since the Notes could be
called as early as August 2019, the total return on the Notes could be minimal. If the Notes are not called, you may be subject to the full downside performance of the Lesser Performing Reference Stock, even though your potential return
is limited to the Coupon Rate. As a result, the return on an investment in the Notes could be less than the return on a direct investment in the Reference Stocks.
|
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
| · |
Your Return May Be Lower than the Return on a Conventional Debt Security of Comparable Maturity — The
return that you will receive on the Notes, which could be negative, may be less than the return you could earn on other investments. Even if your return is positive, your return may be less than the return you would earn if you bought a
conventional senior interest bearing debt security of Royal Bank.
|
| · |
Payments on the Notes Are Subject to Our Credit Risk, and Changes in Our Credit Ratings Are Expected to Affect the
Market Value of the Notes — The Notes are Royal Bank’s senior unsecured debt securities. As a result, your receipt of the coupons and the amount due on any relevant payment date is dependent upon Royal Bank’s ability to repay
its obligations on the applicable payment dates. This will be the case even if the prices of the Reference Stocks increase after the Trade Date. No assurance can be given as to what our financial condition will be during the term of the
Notes.
|
| · |
There May Not Be an Active Trading Market for the Notes-Sales in the Secondary Market May Result in Significant
Losses — There may be little or no secondary market for the Notes. The Notes will not be listed on any securities exchange. RBCCM and other affiliates of Royal Bank may make a market for the Notes; however, they are not
required to do so. RBCCM or any other affiliate of Royal Bank may stop any market-making activities at any time. Even if a secondary market for the Notes develops, it may not provide significant liquidity or trade at prices advantageous
to you. We expect that transaction costs in any secondary market would be high. As a result, the difference between bid and asked prices for your Notes in any secondary market could be substantial.
|
| · |
The Initial Estimated Value of the Notes Will Be Less than the Price to the Public — The initial estimated value set forth on the cover page and that will be set forth in the final pricing supplement for the Notes does not represent a minimum
price at which we, RBCCM or any of our affiliates would be willing to purchase the Notes in any secondary market (if any exists) at any time. If you attempt to sell the Notes prior to maturity, their market value may be lower than the
price you paid for them and the initial estimated value. This is due to, among other things, changes in the prices of the Reference Stocks, the borrowing rate we pay to issue securities of this kind, and the inclusion in the price to
the public of the underwriting discount and the estimated costs relating to our hedging of the Notes. These factors, together with various credit, market and economic factors over the term of the Notes, are expected to reduce the price
at which you may be able to sell the Notes in any secondary market and will affect the value of the Notes in complex and unpredictable ways. Assuming no change in market conditions or any other relevant factors, the price, if any, at
which you may be able to sell your Notes prior to maturity may be less than your original purchase price, as any such sale price would not be expected to include the underwriting discount and the hedging costs relating to the Notes. In
addition to bid-ask spreads, the value of the Notes determined by RBCCM for any secondary market price is expected to be based on the secondary rate rather than the internal funding rate used to price the Notes and determine the initial
estimated value. As a result, the secondary price will be less than if the internal funding rate was used. The Notes are not designed to be short-term trading instruments. Accordingly, you should be able and willing to hold your Notes
to maturity.
|
| · |
The Initial Estimated Value of the Notes on the Cover Page of this Terms Supplement and that We Will Provide in
the Final Pricing Supplement Are Estimates Only, Calculated as of the Time the Terms of the Notes Are Set — The initial estimated value of the Notes will be based on the value of our obligation to make the payments on the
Notes, together with the mid-market value of the derivative embedded in the terms of the Notes. See “Structuring the Notes” below. Our estimates are based on a variety of assumptions, including our credit spreads, expectations as to
dividends, interest rates and volatility, and the expected term of the Notes. These assumptions are based on certain forecasts about future events, which may prove to be incorrect. Other entities may value the Notes or similar
securities at a price that is significantly different than we do.
|
The value of the Notes at any time after the Trade Date will vary based on many factors, including changes in market conditions, and cannot be
predicted with accuracy. As a result, the actual value you would receive if you sold the Notes in any secondary market, if any, should be expected to differ materially from the initial estimated value of your Notes.
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
| · |
Market Disruption Events and Adjustments — The payment at maturity, each Observation Date and the
Valuation Date are subject to adjustment as described in the product prospectus supplement. For a description of what constitutes a market disruption event as well as the consequences of that market disruption event, see “General Terms
of the Notes—Market Disruption Events” in the product prospectus supplement.
|
| · |
Our Business Activities May Create Conflicts of Interest — We and our affiliates expect to engage in
trading activities related to the Reference Stocks that are not for the account of holders of the Notes or on their behalf. These trading activities may present a conflict between the holders’ interests in the Notes and the interests we
and our affiliates will have in their proprietary accounts, in facilitating transactions, including options and other derivatives transactions, for their customers and in accounts under their management. These trading activities, if
they influence the share price of the Reference Stocks, could be adverse to the interests of the holders of the Notes. We and one or more of our affiliates may, at present or in the future, engage in business with the Reference Stock
Issuers, including making loans to or providing advisory services. These services could include investment banking and merger and acquisition advisory services. These activities may present a conflict between our or one or more of our
affiliates’ obligations and your interests as a holder of the Notes. Moreover, we and our affiliates may have published, and in the future expect to publish, research reports with respect to the Reference Stocks. This research is
modified from time to time without notice and may express opinions or provide recommendations that are inconsistent with purchasing or holding the Notes. Any of these activities by us or one or more of our affiliates may affect the
share price of the Reference Stocks, and, therefore, the market value of the Notes.
|
| · |
Owning the Notes Is Not the Same as Owning the Reference Stocks — The return on your Notes is unlikely to
reflect the return you would realize if you actually owned shares of the Reference Stocks. For instance, you will not receive or be entitled to receive any dividend payments or other distributions on these securities during the term of
your Notes. As an owner of the Notes, you will not have voting rights or any other rights that holders of these securities may have. Furthermore, the Reference Stocks may appreciate substantially during the term of the Notes, while your
potential return will be limited to the applicable coupon payments.
|
| · |
You Must Rely on Your Own Evaluation of the Merits of an Investment Linked to the Reference Stocks — In
the ordinary course of their business, our affiliates may have expressed views on expected movements in the Reference Stocks, and may do so in the future. These views or reports may be communicated to our clients and clients of our
affiliates. However, these views are subject to change from time to time. Moreover, other professionals who transact business in markets relating to any Reference Stock may at any time have significantly different views from those of
our affiliates. For these reasons, you are encouraged to derive information concerning the Reference Stocks from multiple sources, and you should not rely solely on views expressed by our affiliates.
|
| · |
There Is No Affiliation Between the Reference Stock Issuers and RBCCM, and RBCCM Is Not Responsible for any
Disclosure by the Reference Stock Issuers — We are not affiliated with the Reference Stock Issuers. However, we and our affiliates may currently, or from time to time in the future engage, in business with any Reference Stock
Issuer. Nevertheless, neither we nor our affiliates assume any responsibilities for the accuracy or the completeness of any information that any other company prepares. You, as an investor in the Notes, should make your own
investigation into the Reference Stocks.
|
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
INFORMATION REGARDING THE REFERENCE STOCKS
The Reference Stocks are registered under the Securities Exchange Act of 1934 (the “Exchange Act”). Companies with securities
registered under that Act are required to file periodically certain financial and other information specified by the SEC. Information provided to or filed with the SEC can be obtained through the SEC’s website at www.sec.gov. In addition,
information regarding the Reference Stocks may be obtained from other sources including, but not limited to, press releases, newspaper articles and other publicly disseminated documents.
The following information regarding the Reference Stock Issuers is derived from publicly available information.
We have not independently verified the accuracy or completeness of reports filed by the Reference Stock Issuers with the SEC,
information published by it on its website or in any other format, information about it obtained from any other source or the information provided below.
We obtained the information regarding the historical performance of the Reference Stocks set forth below from Bloomberg Financial
Markets.
We have not independently verified the accuracy or completeness of the information obtained from Bloomberg Financial Markets. The
historical performance of the Reference Stocks should not be taken as an indication of their future performance, and no assurance can be given as to the market prices of any Reference Stock at any time during the term of the Notes. We cannot give
you assurance that the performance of any Reference Stock will not result in the loss of all or part of your investment.
| · |
Allergan PLC manufactures specialty pharmaceuticals. The company develops, manufactures, and distributes generic, brand, and over-the-counter products. The company’s ordinary shares
are listed on the New York Stock Exchange (the “NYSE”) under the ticker symbol “AGN.”
|
| · |
Bristol-Myers Squibb Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. The company’s products and experimental therapies address
cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders. The company’s common stock is listed on the NYSE under the ticker symbol “BMY.”
|
| · |
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to
advance the care of patients suffering from life-threatening diseases. The company primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions. The company’s common stock is listed on
the Nasdaq under the ticker symbol “GILD.”
|
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
HISTORICAL INFORMATION
The graphs below set forth the information relating to the historical performance of the Reference Stocks for the period from January
1, 2009 through February 11, 2019.
We obtained the information regarding the historical performance of the Reference Stocks in the graphs below from Bloomberg Financial
Markets.
We have not independently verified the accuracy or completeness of the information obtained from Bloomberg Financial Markets. The historical performance of any Reference
Stock should not be taken as an indication of its future performance, and no assurance can be given as to the prices of the Reference Stocks at any time. We cannot give you assurance that the performance of the Reference Stocks will not result in
the loss of all or part of your investment.
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
Historical Information for Allergan PLC (“AGN”)
The graph below illustrates the performance of this Reference Stock from January 1, 2009 to February 11, 2019, assuming an Initial Stock Price of
$134.74, which was the closing price of this Reference Stock on February 11, 2019. The red line represents a hypothetical Trigger Price of $67.37, which is equal to 50.00% of the closing price on February 11, 2019. The actual Trigger Price will be
based on the closing price of this Reference Stock on the Trade Date.
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
Historical Information for Bristol-Myers Squibb Company (“BMY”)
The graph below illustrates the performance of this Reference Stock from July 2, 2015 to February 11, 2019, assuming an Initial Stock Price of $50.10
which was the closing price of this Reference Stock on February 11, 2019. The red line represents a hypothetical Trigger Price of $25.05, which is equal to 50.00% of the closing price on February 11, 2019. The actual Trigger Price will be based on
the closing price of this Reference Stock on the Trade Date.
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
Historical Information for Gilead Sciences, Inc. (“GILD”)
The graph below illustrates the performance of this Reference Stock from January 1, 2009 to February 11, 2019, assuming an Initial Stock Price of
$67.62, which was the closing price of this Reference Stock on February 11, 2019. The red line represents a hypothetical Trigger Price of $33.81, which is equal to 50.00% of the closing price on February 11, 2019. The actual Trigger Price will be
based on the closing price of this Reference Stock on the Trade Date.
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
U.S. FEDERAL TAX INFORMATION
__% of each stated interest payment (11.00% in total) will be treated as an interest payment and __% of each stated interest payment will be treated as
payment for the Put Option for U.S. federal income tax purposes.
The following disclosure supplements, and to the extent inconsistent supersedes, the discussion in the product prospectus supplement dated September 10,
2018 under “Supplemental Discussion of U.S. Federal Income Tax Consequences.”
Under Section 871(m) of the Code, a “dividend equivalent” payment is treated as a dividend from sources within the United States. Such payments generally
would be subject to a 30% U.S. withholding tax if paid to a non-U.S. holder. Under U.S. Treasury Department regulations, payments (including deemed payments) with respect to equity-linked instruments (“ELIs”) that are “specified ELIs” may be
treated as dividend equivalents if such specified ELIs reference an interest in an “underlying security,” which is generally any interest in an entity taxable as a corporation for U.S. federal income tax purposes if a payment with respect to such
interest could give rise to a U.S. source dividend. However, the IRS has issued guidance that states that the U.S. Treasury Department and the IRS intend to amend the effective dates of the U.S. Treasury Department regulations to provide that
withholding on dividend equivalent payments will not apply to specified ELIs that are not delta-one instruments and that are issued before January 1, 2019. Based on our determination that the Notes are not delta-one instruments, non-U.S. holders
should not be subject to withholding on dividend equivalent payments, if any, under the Notes. However, it is possible that the Notes could be treated as deemed reissued for U.S. federal income tax purposes upon the occurrence of certain events
affecting the Reference Stocks or the Notes, and following such occurrence the Notes could be treated as subject to withholding on dividend equivalent payments. Non-U.S. holders that enter, or have entered, into other transactions in respect of the
Reference Stocks or the Notes should consult their tax advisors as to the application of the dividend equivalent withholding tax in the context of the Notes and their other transactions. If any payments are treated as dividend equivalents subject
to withholding, we (or the applicable withholding agent) would be entitled to withhold taxes without being required to pay any additional amounts with respect to amounts so withheld.
SUPPLEMENTAL PLAN OF DISTRIBUTION (CONFLICTS OF INTEREST)
Delivery of the Notes will be made against payment for the Notes on February 19, 2019, which is the third (3rd) business day following the
Trade Date (this settlement cycle being referred to as “T+3”). See “Plan of Distribution” in the prospectus dated September 7, 2018. For additional information as to the relationship between us and RBCCM, please see the section “Plan of
Distribution — Conflicts of Interest” in the prospectus dated September 7, 2018.
We expect to deliver the Notes on a date that is greater than two business days following the Trade Date. Under Rule 15c6-1 of the Exchange Act, trades
in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes more than two business days prior to the original
Issue Date will be required to specify alternative settlement arrangements to prevent a failed settlement.
The value of the Notes shown on your account statement may be based on RBCCM’s estimate of the value of the Notes if RBCCM or another of our affiliates
were to make a market in the Notes (which it is not obligated to do). That estimate will be based upon the price that RBCCM may pay for the Notes in light of then prevailing market conditions, our creditworthiness and transaction costs. For a
period of approximately three months after the issue date of the Notes, the value of the Notes that may be shown on your account statement may be higher than RBCCM’s estimated value of the Notes at that time. This is because the estimated value of
the Notes will not include the underwriting discount and our hedging costs and profits; however, the value of the Notes shown on your account statement during that period may be a higher amount, reflecting the addition of the underwriting discount
and our estimated costs and profits from hedging the Notes. This excess is expected to decrease over time until the end of this period. After this period, if RBCCM repurchases your Notes, it expects to do so at prices that reflect their estimated
value.
We may use this terms supplement in the initial sale of the Notes. In addition, RBCCM or another of our affiliates may use this terms supplement in a
market-making transaction in the Notes after their initial sale. Unless we or our agent informs the purchaser otherwise in the confirmation of sale, this
terms supplement is being used in a market-making transaction.
|
|
|
|
Issuer Callable Fixed Coupon Barrier Notes
Royal Bank of Canada
|
STRUCTURING THE NOTES
The Notes are our debt securities, the return on which is linked to the performance of the Reference Stocks. As is the case for all of our debt
securities, including our structured notes, the economic terms of the Notes reflect our actual or perceived creditworthiness at the time of pricing. In addition, because structured notes result in increased operational, funding and liability
management costs to us, we typically borrow the funds under these Notes at a rate that is more favorable to us than the rate that we might pay for a conventional fixed or floating rate debt security of comparable maturity. Using this relatively
lower implied borrowing rate rather than the secondary market rate, is a factor that is likely to reduce the initial estimated value of the Notes at the time their terms are set. Unlike the estimated value included in this terms supplement or in
the final pricing supplement, any value of the Notes determined for purposes of a secondary market transaction may be based on a different funding rate, which may result in a lower value for the Notes than if our initial internal funding rate were
used.
In order to satisfy our payment obligations under the Notes, we may choose to enter into certain hedging arrangements (which may include call options,
put options or other derivatives) on the issue date with RBCCM or one of our other subsidiaries. The terms of these hedging arrangements take into account a number of factors, including our creditworthiness, interest rate movements, the volatility
of the Reference Stocks, and the tenor of the Notes. The economic terms of the Notes and their initial estimated value depend in part on the terms of these hedging arrangements.
The lower implied borrowing rate is a factor that reduces the economic terms of the Notes to you. The initial offering price of the Notes also
reflects the underwriting commission and our estimated hedging costs. These factors result in the initial estimated value for the Notes on the Trade Date being less than their public offering price. See “Selected Risk Considerations — The Initial
Estimated Value of the Notes Will Be Less than the Price to the Public” above.